insulin

CSII-Sun Yat-sen University-type 2 diabetes mellitus refers to the use of Continuous Subcutaneous Insulin Infusion (CSII) as a short-term intensive insulin therapy (SIIT) protocol, which has been a major research focus at Sun Yat-sen University. This intervention involves the administration of insulin via an external pump for a duration of 2 to 4 weeks in patients with newly diagnosed type 2 diabetes mellitus. The primary goal of this intensive treatment is to rapidly achieve euglycemia, thereby alleviating glucose toxicity and providing 'rest' to pancreatic beta cells. Clinical studies led by researchers at Sun Yat-sen University have demonstrated that this short-term intensive intervention can lead to significant recovery of beta-cell function and induce long-term glycemic remission, allowing some patients to maintain target blood glucose levels without the need for oral medications for extended periods. The protocol is often evaluated as a standalone therapy or in combination with other agents such as GLP-1 receptor agonists (e.g., liraglutide) to preserve metabolic benefits.

Other names

CSIIContinuous Subcutaneous Insulin InfusionShort-term Intensive Insulin TherapySIITIntensive Insulin Pump Therapy